VACCINATION UPTAKE IN A COHORT OF PATIENTS ON BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) AT A MELBOURNE PUBLIC HOSPITAL

被引：0
|
作者：
Pourhadi, H. [1 ]
Johnson, A. [1 ]
Foote, A. [1 ]
机构：
[1] Northern Hlth, Rheumatol, Epping, NSW, Australia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
COVID; bDMARD; Vaccination/Immunization;
D O I：
10.1136/annrheumdis-2023-eular.5416
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1812-HPR
引用
收藏
页码：2139 / 2139
页数：1
相关论文
共 50 条
  • [31] The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States
    Ding, Qian
    Shiltz, Dane
    Hossami, Dana
    Konieczny, Alison M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (08) : 1231 - 1241
  • [32] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC AND NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 374 - 375
  • [33] Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis
    Knowles, Susan
    Taroumian, Sara
    Lisse, Jeffrey R.
    Yanes, James
    Ampel, Neil M.
    Gall, Eric P.
    Grau, Rafael G.
    Bode, Barbara Y.
    Vaz, Berchman A.
    Galgiani, John
    Hoover, Susan E.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S961 - S961
  • [34] Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia
    Machado-Alba, J. E.
    Ruiz, A. F.
    Machado-Duque, M. E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (06) : 506 - 511
  • [35] Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Cho, Soo-Kyung
    Kim, Hyoungyoung
    Song, Yeo-Jin
    Kim, Hye Won
    Nam, Eunwoo
    Lee, Shin-Seok
    Lee, Hye-Soon
    Park, Sung-Hoon
    Lee, Yeon-Ah
    Park, Min-Chan
    Chang, Sung Hae
    Kim, Hyoun-Ah
    Kwok, Seung-Ki
    Kim, Hae-Rim
    Kim, Hyun-Sook
    Yoon, Bo Young
    Uhm, Wan-Sik
    Kim, Yong-Gil
    Kim, Jae Hoon
    Lee, Jisoo
    Choi, Jeongim
    Sung, Yoon-Kyoung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (04): : 546 - +
  • [36] FACTORS ASSOCIATED WITH INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hammou, O.
    Chennouf, F.
    Azzouzi, H.
    Linda, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1441 - 1441
  • [37] Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis
    Wendling, Daniel
    Goupille, Philippe
    IMMUNOTHERAPY, 2020, 12 (12) : 857 - 860
  • [38] Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
    Razak, Salmi Abdul
    Bakry, Mohd Makmor
    Said, Mohd Shahrir Mohamed
    Tan, Chai-Eng
    Redzuan, Adyani Md
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [39] Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children
    Cron, Randy Q.
    CURRENT OPINION IN RHEUMATOLOGY, 2022, 34 (05) : 274 - 279
  • [40] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
12345